NSEGeneral Updates2d ago · 23 Sept 2026, 06:20 pm
General Updates
Emcure Pharmaceuticals Limited · EMCURE
✦ AI SummaryMgmt Change
Emcure Pharmaceuticals Limited has informed the Exchange about change in composition of the Board of the Company, following the 45th Annual General Meeting (AGM) held on September 21, 2026. The AGM approved the retirement of Mr. Berjis Desai, re-appointment of Dr. Mukund Gurjar and Mr. Satish Mehta, and appointment of Mr. Raghu Kumar as Independent Director.
Analysis Scores
Earnings Impact2/10
Growth Catalyst3/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
EMCURE: Emcure Pharmaceuticals Limited has informed the Exchange about change in composition of the Board of the Company.
Attachments (1)
📄pdf
Download →
EMCURE_23092026182025_EPLUpdateonAGMresolutions.pdf
View document text
Emcure
Ref: EPL/CS/SE/0084/2026 Date: September 23, 2026
National Stock Exchange of India Limited BSE Limited
Exchange Plaza, C-1, Block G, P J Towers,
Bandra Kurla Complex, Bandra (East), Dalal Street,
Mumbai – 400 051 Mumbai- 400 001
Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE
Dear Sir/Madam,
Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 – Change in composition of the Board of the
Company
We refer to our disclosure dated May 05, 2026 and August 06, 2026 and pursuant to the
provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 (‘SEBI Listing Regulations’), this is to inform you that the Members of the
Company, at the 45th Annual General Meeting (“AGM”) of the Company held on Monday,
September 21, 2026 at 11.00 a.m. (IST) have, inter-alia, approved:
Retirement of Mr. Berjis Desai (DIN: 00153675), Chairman and Non-Executive
Non-Independent Director upon the conclusion of this AGM, i.e., September 21, 2026.
Re-appointment of Dr. Mukund Gurjar (DIN: 00026843) as a Whole-time Director of the
Company for a further period of one (1) year commencing from August 28, 2026.
Re-appointment of Mr. Satish Mehta (DIN: 00118691) as a Managing Director &
Chief Executive Officer of the Company a further period of 5 (five) years commencing
from April 01, 2027.
Appointment of Mr. Raghu Kumar (DIN: 01983106) as an Independent Director of the
Company for first term of three (3) consecutive years, with effect from August 06, 2026.
The voting results of 45th AGM of the Members of the Company have been submitted with
both the Stock Exchanges on September 23, 2026.
You are requested to take the above information on your records.
Thanking you,
For Emcure Pharmaceuticals Limited
Amruta Yangalwar
Company Secretary & Compliance Officer
ICSI Membership Number: A25687
Emcure Pharmaceuticals Limited
Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India
Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060
E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251